

### **Remarks**

Claims 69, 92, 95, 96, and 98 are rejected under 35 U.S.C. § 112 ¶ 1 as containing new matter. Claims 69 and 92-98 are rejected under 35 U.S.C. § 112 ¶ 1 as not enabled for their full scope. To advance prosecution, Applicants have canceled all but claims 93 and 94 and have amended claim 93 to recite that the composition is administered intratumorally. The Examiner acknowledges that the specification enables a method of inhibiting tumor cell growth in an animal via intratumoral administration of HVJ-E.

Respectfully submitted,

**BANNER & WITCOFF, LTD.**

/Lisa M. Hemmendinger/

By: \_\_\_\_\_

Lisa M. Hemmendinger  
Registration No. 42,653

Date: October 4, 2010

Customer No. 22907  
202-824-3000